Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyBCBSOK Specialty Pharmacy Prior Auth Update | Open…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - OklahomaPolicy N/A

    Commercial Outpatient Specialty Pharmacy Prior Authorization Codes (Effective 1/1/2026)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Oklahoma policy alerts

    Know when Blue Cross Blue Shield - Oklahoma releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    A searchable list of procedure (J/Q/9-series) codes for Medical Benefit Specialty Pharmacy that may require prior authorization for BCBSOK commercial members, including delegation notes for Carelon (medical oncology & supportive care) vs BCBSOK reviews.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyCommercial Outpatient Specialty Pharmacy Prior Authorization Codes (Effective 1/1/2026)
    Policy CodePolicy N/A
    Change TypeAdded multiple procedure codes and clarified delegation for Carelon vs BCBSOK
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSend prior authorization requests to Carelon for oncology drugs supported by an oncology diagnosis; send PA requests to BCBSOK for provider-administered therapy or infusion site-of-care.
    SourceLink
    POLICY UPDATE CHANGES

    Multiple procedure codes and their managed-by assignments and effective dates were added with effective dates 1/1/2026 and 7/1/2026.

    Delegation for oncology drug prior authorization clarified: Carelon reviews oncology drugs supported by an oncology diagnosis; BCBSOK reviews provider-administered therapy or oncology drugs without oncology diagnosis.

    J1562 (Vivaglobin) entry marked for removal effective 4/1/2026.

    50+procedure codes listed in this partial extract (J/Q/9/902 series)
    1/1/2026 & 7/1/2026effective dates used repeatedly for added codes
    CarelonPrior authorization vendor repeatedly referenced
    Carelon or BCBSmanaged-by assignments for many codes
    searchable PDFdocument format and use instruction

    Coverage, Routing, and Delegation Rules

    Delegation criteria

    Management assignment determines where the prior authorization medical necessity review is performed.

    Carelon will review requests for oncology drugs that are supported by an oncology diagnosis.
    BCBSOK will review requests for provider-administered therapy, infusion site of care services, or drugs that are not associated with an oncology diagnosis.
    When an entry indicates 'Carelon or BCBS' the managed-by assignment may vary; follow the routing note: send PA requests to Carelon for Medical Oncology & Supportive Care when supported by an oncology diagnosis; otherwise send PA requests to BCBSOK.

    Removals

    Effective date change / removal examples from extract.

    J1562 (Immune Globulin (Vivaglobin) 100 mg) — Remove effective 4/1/2026.

    Administrative coverage notes

    Administrative coverage notes and prior authorization routing

    Unclassified HCPCS codes (e.g., J0642, J3490, J9011) are designated as 'Code represents unclassified drugs or biologics' and require prior authorization through Carelon.
    Multiple J- and Q-codes are listed with service categories such as 'Infusion Site of Care' or 'Provider Administered Drug Therapy' and include administrative notes indicating additions effective on specific future dates; follow the listed managed-by assignment and effective-date notes when determining PA routing.

    Coverage and routing criteria

    Routing and coverage stance for injectable oncology drugs:

    Most listed J- and Q- codes mapped to 'Medical Oncology & Supportive Care' are routed to Carelon for review.
    Not Otherwise Classified antineoplastic codes (e.g., J9999) and other unclassified biologics require prior authorization via Carelon.
    Many entries include effective-date administrative notes (e.g., additions effective 4/1/2026) that change mappings or when products will be reviewed under a particular code; apply the effective date shown in the entry when determining routing and review responsibility.
    Carelon will only review oncology drugs that are supported by an oncology diagnosis; if not supported by an oncology diagnosis the request will be reviewed by BCBS.

    Review responsibility rules (excerpt)

    Routing and review responsibility for provider-administered drugs (excerpt):

    ONE of: Drug is an oncology therapy and the request includes an oncology diagnosis (route to Carelon).
    ONE of: Service is Provider Administered Drug Therapy or Infusion Site of Care without an oncology diagnosis (route to BCBSOK).
    Entries marked 'Carelon or BCBS' indicate dual possible management; follow the specific per-code assignment and diagnosis support requirement to determine which entity will perform the PA review.

    Procedure Codes and Mappings (J/Q/9-series)

    Covered HCPCS J-codes (selected additions effective 1/1/2026)HCPCSCovered
    J0174Injection, lecanemab-irmb, 1 mg (Add effective 1/1/2026)
    J0175Injection, donanemab-azbt, 2 mg (Add effective 1/1/2026)
    J2508Injection, pegunigalsidase alfa-iwxj, 1 mg (Add effective 1/1/2026)
    Covered HCPCS J-codes (infusion site-of-care selected)HCPCSCovered
    J2354Injection Octreotide non-depot 25 mcg
    J2356Injection Tezepelumab-Ekko 1 mg
    J2357Injection Omalizumab 5 mg
    J2507Injection Pegloticase 1 mg
    J2786Injection Reslizumab 1 mg
    Covered HCPCS J-codes (additional infusion J-codes)HCPCSCovered
    J3032Injection Eptinezumab-Jjmr 1 mg
    J3060Injection Taliglucerase Alfa 10 units
    J3111Injection Romosozumab-Aqqg 1 mg
    J3241Injection Teprotumumab-Trbw 10 mg
    J3262Injection Tocilizumab 1 mg
    Covered HCPCS J-codes (biosimilars & Q-code mappings)mixedCovered
    Q5123Injection Rituximab-Arrx (Riabni) 10 mg (Add effective 1/1/2026)
    Q5103Injection Infliximab-Dyyb (Inflectra) 10 mg
    Q5104Injection Infliximab-Abda (Renflexis) 10 mg
    Q5121Injection Infliximab-Axxq (Avsola) 10 mg
    Q5133Injection Tocilizumab-Bavi (Tofidence) biosimilar 1 mg
    Covered HCPCS J-codes (unclassified drug/biologic codes)HCPCSCovered
    J0642Unclassified Drugs Or Biologicals - Levoleucovorin (Khapzory) 0.5 mg; prior auth through Carelon
    J3490Unclassified Drugs - prior authorization required through Carelon
    J9011Unclassified Biologics - datopotamab deruxtecan-dlnk 1 mg; prior authorization required through Carelon
    Neutral sample J/Q codes mapped to Medical Oncology & Supportive Caremixed
    J9024Injection Avelumab 10 mg (mapped to Medical Oncology & Supportive Care)
    Q2050Sipuleucel-T related mapping (Medical Oncology & Supportive Care)
    Q5107Bevacizumab-Awwb (Mvasi) biosimilar 10 mg (Carelon)

    Where and How to Submit Prior Authorization Requests

    Note

    How to use list

    This file is a searchable PDF. Press "CTRL" and "F" keys at the same time to bring up the search box. Enter a procedure code or description of the service to quickly locate a code and view prior authorization requirements, including whether prior authorization applies to therapy only (Provider Administered Drug Therapy), to place of infusion (Infusion Site of Care), or to Medical Oncology & Supportive Care (managed by Carelon).

    Prior Authorization

    Prior Authorization Routing

    Send prior authorization requests to BCBSOK for Provider Administered Therapy or Infusion Site of Care. Send prior authorization requests to Carelon Medical Benefits Management for Medical Oncology & Supportive Care when the drug requested is supported by an oncology diagnosis. Carelon will only review oncology drug requests that have an oncology diagnosis; if the drug requested is not associated with an oncology diagnosis, BCBSOK will review the request. Refer to the Update History / Prior Authorization Delegation Notes for details.

    • BCBSOK = Provider Administered Therapy or Infusion Site of Care
    • Carelon = Medical Oncology & Supportive Care (only for requests supported by an oncology diagnosis)

    Defined Terms and Code Notes

    Carelon
    DefinitionCarelon Medical Benefits Management
    RoleIndependent contractor that provides utilization management services for BCBSOK, including review of Medical Oncology & Supportive Care requests when assigned to Carelon.
    PA routingSend prior authorization requests for Medical Oncology & Supportive Care (when drug is supported by an oncology diagnosis) to Carelon per the document instructions.
    BCBSOK
    DefinitionBCBSOK (Blue Cross Blue Shield of Oklahoma)
    RoleReviews Provider Administered Therapy or Infusion Site of Care requests and reviews oncology drugs that are not supported by an oncology diagnosis.
    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyCommercial Outpatient Specialty Pharmacy Prior Authorization Codes (Effective 1/1/2026)
    Policy CodePolicy N/A
    Change TypeAdded multiple procedure codes and clarified delegation for Carelon vs BCBSOK
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSend prior authorization requests to Carelon for oncology drugs supported by an oncology diagnosis; send PA requests to BCBSOK for provider-administered therapy or infusion site-of-care.
    SourceLink
    On This Page
    Coverage, Routing, and Delegation RulesProcedure Codes and Mappings (J/Q/9-series)Where and How to Submit Prior Authorization RequestsDefined Terms and Code Notes
  1. If a drug has multiple indications or is not associated with an oncology diagnosis, route per delegation notes — Carelon may not review non-oncology indications.
  2. Prior Authorization

    Unclassified biologics prior auth

    Codes that represent unclassified drugs or biologics (for example J0642, J3490, J9999 and other 'Not Otherwise Classified' or 'Unclassified' HCPCS codes) require prior authorization through Carelon when the request is for Medical Oncology & Supportive Care and is supported by an oncology diagnosis. These unclassified codes are managed by Carelon per the code-specific entries in this file; when an unclassified code maps to a specific branded product and a different HCPCS becomes the appropriate code (per updates), that mapping and effective date are noted in the code entries.

    • Examples: J0642, J3490, J9999 — code entries indicate these represent unclassified drugs/biologics and are managed by Carelon
    • Prior Authorization required through Carelon for unclassified/Not Otherwise Classified antineoplastic drugs or biologics when reviewed as Medical Oncology & Supportive Care
    • See individual code entries for specific drugs and effective dates (some drugs moved to specific J- or Q-codes on later effective dates).
    PA routingSend prior authorization requests for Provider Administered Therapy or Infusion Site of Care to BCBSOK as directed in the list.
    Carelon prior authorization
    RequirementPrior authorization required through Carelon for certain codes and unclassified drugs/biologics listed as Medical Oncology & Supportive Care (e.g., J0642, J3490 entries).
    ScopeCarelon handles prior authorization for Medical Oncology & Supportive Care entries and unclassified drug codes when assigned to Carelon in the listing.
    ReferenceSee specific code entries in the searchable PDF for which HCPCS/J/Q codes require PA via Carelon and their effective dates.
    Unclassified drug/biologic (examples)
    Code examplesJ0642, J3490, J9011 (listed as unclassified drugs or biologics in the extract).
    MeaningThese HCPCS codes represent 'Unclassified Drugs Or Biologicals' or 'Unclassified Drugs' where specific product-level mapping is not assigned to a unique J/Q code in the extract.
    PA routingPrior authorization for these unclassified entries is routed to Carelon where indicated in the listing.
    J9999 (unclassified antineoplastic)
    Code exampleJ9999
    MeaningJ9999 is used for 'Not Otherwise Classified Antineoplastic Drugs' or unclassified biologics per the extract.
    PA requirementPrior authorization required through Carelon for J9999 as indicated in the code listing.
    Q2050 (Sipuleucel‑T)
    CodeQ2050
    DescriptionSipuleucel‑T — minimum of 50 million autologous CD54+ cells activated with PAP‑GM‑CSF per infusion.
    Managed byAssigned to Medical Oncology & Supportive Care and routed to Carelon in the extract.
    Carelon review routing
    Routing ruleCarelon will review requests for oncology drugs that are supported by an oncology diagnosis.
    If not oncologyIf the requested drug is not associated with an oncology diagnosis, BCBSOK will review the request.
    Operational noteDelegation and routing details are provided in the searchable PDF and Update History / Prior Authorization Delegation Notes.
    Payment guarantee disclaimer
    Payment disclaimerChecking eligibility, benefits, or prior authorization does not guarantee payment; benefits are determined at claim adjudication per the member's certificate of coverage.
    Action for providersSubmit claims for adjudication; confirmation of PA or eligibility is not a payment guarantee.
    ReferenceSee CPT/rights and payment guarantee disclaimer in the document footer and full policy PDF.